A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Trial Profile

A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs AZD 4547 (Primary)
  • Indications Lung cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms Lung-MAP
  • Most Recent Events

    • 06 Jun 2017 Results (n=28) assessing safety and efficacy in biomarker enriched cohort, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top